問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
黃彥筑
下載
2019-09-01 - 2027-12-31
Condition/Disease
Test Drug
Participate Sites5Sites
Recruiting5Sites
2024-05-01 - 2032-12-31
2023-05-01 - 2027-06-24
Participate Sites12Sites
Recruiting12Sites
2023-05-09 - 2026-07-31
Participate Sites4Sites
Recruiting4Sites
2023-05-10 - 2025-04-30
Participate Sites3Sites
Recruiting3Sites
2020-04-01 - 2026-09-01
2017-11-01 - 2021-12-08
Acute primary cerebral hemorrhage
Three-dose combination(telmisartan, amlodipine, indapamide)
Study ended1Sites
Division of Neurology
全部
